Zacks Research Downgrades Pharming Group (NASDAQ:PHAR) to Strong Sell

Pharming Group (NASDAQ:PHAR) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Other equities analysts also recently issued reports about the company. HC Wainwright set a $37.00 price target on Pharming Group and gave the stock a “buy” rating in a research report on Thursday. Wall Street Zen raised Pharming Group to a “strong-buy” rating in a research report on Saturday, December 27th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pharming Group in a report on Monday, December 22nd. Finally, Oppenheimer restated an “outperform” rating and set a $41.00 price objective (down from $42.00) on shares of Pharming Group in a report on Friday. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Pharming Group has a consensus rating of “Hold” and an average target price of $39.00.

Pharming Group Stock Performance

PHAR stock opened at $14.51 on Thursday. Pharming Group has a one year low of $7.50 and a one year high of $21.34. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of 1,451.00 and a beta of 0.04. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.39 and a current ratio of 3.16. The firm has a 50-day simple moving average of $17.21 and a two-hundred day simple moving average of $16.06.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, March 12th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.08). Pharming Group had a return on equity of 1.12% and a net margin of 0.71%.The firm had revenue of $106.50 million for the quarter, compared to the consensus estimate of $111.76 million. On average, equities analysts forecast that Pharming Group will post -0.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

A number of large investors have recently bought and sold shares of PHAR. NewEdge Advisors LLC raised its position in Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after buying an additional 28,615 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Pharming Group in the 4th quarter valued at $360,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Pharming Group in the fourth quarter worth $224,000. Finally, EverSource Wealth Advisors LLC purchased a new position in shares of Pharming Group during the second quarter worth $32,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group News Roundup

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: Company set a 2026 revenue target of $405M–$425M, citing growth from Joenja and RUCONEST as primary drivers — this provides clear growth levers for next year and supports upside if execution meets targets. Pharming outlines $405M–$425M 2026 revenue target
• Positive Sentiment: Company reported full-year and Q4 2025 revenue growth and positive cash flow and reaffirmed 2026 guidance — fundamentals showing improving cash generation can reduce funding risk and support valuation. Pharming Group reports fourth quarter and full year 2025 financial results
• Positive Sentiment: Oppenheimer reiterated an “Outperform” rating with a $41 price target (slightly trimmed), signaling continued bullish analyst conviction and implying substantial upside from current levels. Oppenheimer reaffirms outperform on PHAR
• Neutral Sentiment: HC Wainwright maintains a Buy rating and $37 target but lowered FY2026 EPS from $0.49 to $0.35 — the firm still expects material 2026 profitability, but the cut shows some model uncertainty around timing and magnitude of margin expansion. HC Wainwright updates estimates for PHAR
• Negative Sentiment: Q4 results missed expectations: revenue $106.5M vs. analyst ~$111.8M and EPS $0.07 vs. $0.15 expected — the quarter’s misses likely triggered the intraday sell-off despite upbeat guidance. Pharming Q4 2025 press release

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.